LAMEA RNA Based Therapeutic Market By Type, By Application, By End User, By Country, Opportunity Analysis and Industry Forecast, 2021-2027

The Latin America, Middle East and Africa RNA Based Therapeutic Market is expected to witness market growth of 17.2% CAGR during the forecast period (2021-2027).

RNA therapies and vaccines that have been given orphan classification by regulatory agencies have a lot of pricing flexibility. Developers have benefited from this, as well as regulatory exclusivity. The absence of other treatment alternatives for rare disorders also aided the expansion of RNA-based medicines and vaccines. Along with these factors, the increased focus of legislative bodies on setting reimbursement laws has accelerated the creation of RNA molecules.

The healthcare industry has been collaborating to bring stability to RNA molecules in the body that has low bioavailability. When coupled with protein/lipid nanoparticles, RNA therapies give improved stability. RNA treatments have been intensively investigated, despite the fact that they are still in the clinical research phase, with the primary goal of treating challenging disorders.

LAMEA is also a lucrative hub for the RNA-based therapeutic market. RNA-based therapeutics is a moderately new class of treatment representing significant potential and growth for the treatment of severe and rare diseases. RNA-based therapeutics are gaining significance for several disease targets, such as HIV, cancer, etc. The growing prevalence of genetic disorders and lack of proper treatment is generating high demand for the development of RNA-based therapeutics. Moreover, South Africa displays a higher requirement for a treatment solution for multiple diseases. Additionally, countries like Brazil and Argentina are already developed. People across these countries comprise significant spending capacity to enhance their lifestyle.

The Brazil market dominated the LAMEA RNA Based Therapeutic Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $129.9 million by 2027. The Argentina market is anticipated to grow at a CAGR of 17.8% during (2021 - 2027). Additionally, The UAE market is expected to showcase a CAGR of 16.9% during (2021 - 2027).

Based on Type, the market is segmented into RNA Antisense and RNA Interference (RNAi). Based on Application, the market is segmented into Genetic disorders and Auto immune disorders. Based on End User, the market is segmented into Research Institutes and Hospitals & Clinics. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., Benitec Biopharma, Inc., Alnylam Pharmaceuticals, Inc., Sanofi S.A. (Sanofi Genzyme), Biogen, Inc., Gradalis, Inc., Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and Silence Therapeutics Plc.

Scope of the Study

Market Segments Covered in the Report:

By Type

• RNA Antisense
• RNA Interference (RNAi)

By Application

• Genetic disorders
• Auto immune disorders

By End User

• Research Institutes
• Hospitals & Clinics

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Arbutus Biopharma Corporation
• Arrowhead Pharmaceuticals, Inc.
• Benitec Biopharma, Inc.
• Alnylam Pharmaceuticals, Inc.
• Sanofi S.A. (Sanofi Genzyme)
• Biogen, Inc.
• Gradalis, Inc.
• Ionis Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.
• Silence Therapeutics Plc

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free